A Phase Ib/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory T-cell lymphomas Meeting Abstract
| Authors: | Mehta-Shah, N.; Moskowitz, A. J.; Lunning, M.; Lynch, P.; Scheuerman, M.; Kumar, A.; Gerecitano, J. F.; Zelenetz, A. D.; Hamlin, P. A. Jr; Noy, A.; Matasar, M. J.; Palomba, M. L.; Younes, A.; Schaffer, W.; Grewal, R.; Rademaker, J.; Sauter, C. S.; Dahi, P. B.; Myskowski, P.; Kheterpal, M.; Dogan, A.; Pulitzer, M.; Tang, L.; Ni, A.; Horwitz, S. M. |
| Abstract Title: | A Phase Ib/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory T-cell lymphomas |
| Meeting Title: | 58th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 128 |
| Issue: | 22 |
| Meeting Dates: | 2016 Dec 3-6 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2016-12-02 |
| Language: | English |
| ACCESSION: | WOS:000394452308040 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood.V128.22.2991.2991 |
| Notes: | Meeting Abstract: 2991 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work